Clinical Trial Update: A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Clinical trial update for PF-08046054/SGN-PDL1V in advanced solid tumors shows a Phase 1 study is currently recruiting across multiple indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Esophageal Squamous Cell Carcinoma
• Gastric Cancer
• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer
• Pancreatic Adenocarcinoma
• Squamous Cell Carcinoma of the Head and Neck
• Triple-negative Breast Cancer

Drugs mentioned

• PF-08046054/SGN-PDL1V

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Status: RECRUITING